Prm21 - Modelling Survival of Patients With Completely Resected Advanced Melanoma With Adjuvant Treatment of Nivolumab Versus Observation
Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.2145
Full Text
Open PDFAbstract
Available in full text
Date
October 1, 2018
Authors
Publisher
Elsevier BV